Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

Current Opinion in Oncology is a prestigious journal published by Lippincott Williams & Wilkins, which has provided a critical platform for researchers and clinicians alike since its inception in 1989. With an ISSN of 1040-8746 and an E-ISSN of 1531-703X, this journal focuses on delivering insightful reviews and discussions that highlight the latest advancements, challenges, and future directions in the field of oncology. It is ranked in the second quartile (Q2) for both Cancer Research and Oncology, reflecting its influential position within the academic community, and it holds Scopus ranks of #125 in Medicine (Oncology) and #103 in Biochemistry, Genetics, and Molecular Biology (Cancer Research). The journal does not offer Open Access but remains accessible through various academic platforms. Its commitment to advancing the understanding of oncology makes it an essential resource for professionals, researchers, and students dedicated to improving cancer care and research.

Advances in Radiation Oncology, published by Elsevier Inc, is a premier international journal dedicated to the field of oncology and radiology, focusing on the latest groundbreaking research and innovations in radiation therapy. Launched as an Open Access journal in 2016, it has since carved out a significant niche in the academic community, featuring contributions that span a diverse range of topics including clinical practices, technologies, and outcomes in radiation oncology. With an impressive Q2 rankingOncology and Radiology, Nuclear Medicine and Imaging categories for 2023, and positioned within the 65th and 55th percentiles of Scopus ranks, it serves as an essential resource for researchers, medical professionals, and students alike. The journal not only emphasizes the importance of disseminating knowledge widely through its open access model but also aims to foster collaboration and innovation in the evolving landscape of cancer treatment. For those looking to stay at the forefront of radiotherapy research and advancements, Advances in Radiation Oncology is an invaluable platform for scholarly communication.

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.